Annual Report to the Nation on the Status of Cancer, part II: Recent changes in prostate cancer trends and disease characteristics
BACKGROUND Temporal trends in prostate cancer incidence and death rates have been attributed to changing patterns of screening and improved treatment (mortality only), among other factors. This study evaluated contemporary national‐level trends and their relations with prostate‐specific antigen (PSA...
Uloženo v:
| Vydáno v: | Cancer Ročník 124; číslo 13; s. 2801 - 2814 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
Wiley Subscription Services, Inc
01.07.2018
John Wiley and Sons Inc |
| Témata: | |
| ISSN: | 0008-543X, 1097-0142, 1097-0142 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | BACKGROUND
Temporal trends in prostate cancer incidence and death rates have been attributed to changing patterns of screening and improved treatment (mortality only), among other factors. This study evaluated contemporary national‐level trends and their relations with prostate‐specific antigen (PSA) testing prevalence and explored trends in incidence according to disease characteristics with stage‐specific, delay‐adjusted rates.
METHODS
Joinpoint regression was used to examine changes in delay‐adjusted prostate cancer incidence rates from population‐based US cancer registries from 2000 to 2014 by age categories, race, and disease characteristics, including stage, PSA, Gleason score, and clinical extension. In addition, the analysis included trends for prostate cancer mortality between 1975 and 2015 by race and the estimation of PSA testing prevalence between 1987 and 2005. The annual percent change was calculated for periods defined by significant trend change points.
RESULTS
For all age groups, overall prostate cancer incidence rates declined approximately 6.5% per year from 2007. However, the incidence of distant‐stage disease increased from 2010 to 2014. The incidence of disease according to higher PSA levels or Gleason scores at diagnosis did not increase. After years of significant decline (from 1993 to 2013), the overall prostate cancer mortality trend stabilized from 2013 to 2015.
CONCLUSIONS
After a decline in PSA test usage, there has been an increased burden of late‐stage disease, and the decline in prostate cancer mortality has leveled off. Cancer 2018;124:2801‐2814. © 2018 American Cancer Society
For the first time, the US cancer surveillance community has performed an analysis of long‐term trends in the incidence of prostate cancer by stage with delay‐adjusted rates. According to nationwide cancer registry and vital registration data, prostate cancer incidence rates for distant‐stage disease have increased and mortality rates for all stages combined have leveled off in the United States since the US Preventive Services Task Force recommendations against prostate‐specific antigen–based screening.See also pages 2785‐800 and 2690‐2. |
|---|---|
| AbstractList | BACKGROUNDTemporal trends in prostate cancer incidence and death rates have been attributed to changing patterns of screening and improved treatment (mortality only), among other factors. This study evaluated contemporary national‐level trends and their relations with prostate‐specific antigen (PSA) testing prevalence and explored trends in incidence according to disease characteristics with stage‐specific, delay‐adjusted rates.METHODSJoinpoint regression was used to examine changes in delay‐adjusted prostate cancer incidence rates from population‐based US cancer registries from 2000 to 2014 by age categories, race, and disease characteristics, including stage, PSA, Gleason score, and clinical extension. In addition, the analysis included trends for prostate cancer mortality between 1975 and 2015 by race and the estimation of PSA testing prevalence between 1987 and 2005. The annual percent change was calculated for periods defined by significant trend change points.RESULTSFor all age groups, overall prostate cancer incidence rates declined approximately 6.5% per year from 2007. However, the incidence of distant‐stage disease increased from 2010 to 2014. The incidence of disease according to higher PSA levels or Gleason scores at diagnosis did not increase. After years of significant decline (from 1993 to 2013), the overall prostate cancer mortality trend stabilized from 2013 to 2015.CONCLUSIONSAfter a decline in PSA test usage, there has been an increased burden of late‐stage disease, and the decline in prostate cancer mortality has leveled off. Cancer 2018;124:2801‐2814. © 2018 American Cancer Society Temporal trends in prostate cancer incidence and death rates have been attributed to changing patterns of screening and improved treatment (mortality only), among other factors. This study evaluated contemporary national-level trends and their relations with prostate-specific antigen (PSA) testing prevalence and explored trends in incidence according to disease characteristics with stage-specific, delay-adjusted rates. Joinpoint regression was used to examine changes in delay-adjusted prostate cancer incidence rates from population-based US cancer registries from 2000 to 2014 by age categories, race, and disease characteristics, including stage, PSA, Gleason score, and clinical extension. In addition, the analysis included trends for prostate cancer mortality between 1975 and 2015 by race and the estimation of PSA testing prevalence between 1987 and 2005. The annual percent change was calculated for periods defined by significant trend change points. For all age groups, overall prostate cancer incidence rates declined approximately 6.5% per year from 2007. However, the incidence of distant-stage disease increased from 2010 to 2014. The incidence of disease according to higher PSA levels or Gleason scores at diagnosis did not increase. After years of significant decline (from 1993 to 2013), the overall prostate cancer mortality trend stabilized from 2013 to 2015. After a decline in PSA test usage, there has been an increased burden of late-stage disease, and the decline in prostate cancer mortality has leveled off. Cancer 2018;124:2801-2814. © 2018 American Cancer Society. For the first time, the US cancer surveillance community has performed an analysis of long‐term trends in the incidence of prostate cancer by stage with delay‐adjusted rates. According to nationwide cancer registry and vital registration data, prostate cancer incidence rates for distant‐stage disease have increased and mortality rates for all stages combined have leveled off in the United States since the US Preventive Services Task Force recommendations against prostate‐specific antigen–based screening.See also pages 2785‐800 and 2690‐2. BACKGROUND Temporal trends in prostate cancer incidence and death rates have been attributed to changing patterns of screening and improved treatment (mortality only), among other factors. This study evaluated contemporary national‐level trends and their relations with prostate‐specific antigen (PSA) testing prevalence and explored trends in incidence according to disease characteristics with stage‐specific, delay‐adjusted rates. METHODS Joinpoint regression was used to examine changes in delay‐adjusted prostate cancer incidence rates from population‐based US cancer registries from 2000 to 2014 by age categories, race, and disease characteristics, including stage, PSA, Gleason score, and clinical extension. In addition, the analysis included trends for prostate cancer mortality between 1975 and 2015 by race and the estimation of PSA testing prevalence between 1987 and 2005. The annual percent change was calculated for periods defined by significant trend change points. RESULTS For all age groups, overall prostate cancer incidence rates declined approximately 6.5% per year from 2007. However, the incidence of distant‐stage disease increased from 2010 to 2014. The incidence of disease according to higher PSA levels or Gleason scores at diagnosis did not increase. After years of significant decline (from 1993 to 2013), the overall prostate cancer mortality trend stabilized from 2013 to 2015. CONCLUSIONS After a decline in PSA test usage, there has been an increased burden of late‐stage disease, and the decline in prostate cancer mortality has leveled off. Cancer 2018;124:2801‐2814. © 2018 American Cancer Society For the first time, the US cancer surveillance community has performed an analysis of long‐term trends in the incidence of prostate cancer by stage with delay‐adjusted rates. According to nationwide cancer registry and vital registration data, prostate cancer incidence rates for distant‐stage disease have increased and mortality rates for all stages combined have leveled off in the United States since the US Preventive Services Task Force recommendations against prostate‐specific antigen–based screening.See also pages 2785‐800 and 2690‐2. Temporal trends in prostate cancer incidence and death rates have been attributed to changing patterns of screening and improved treatment (mortality only), among other factors. This study evaluated contemporary national-level trends and their relations with prostate-specific antigen (PSA) testing prevalence and explored trends in incidence according to disease characteristics with stage-specific, delay-adjusted rates.BACKGROUNDTemporal trends in prostate cancer incidence and death rates have been attributed to changing patterns of screening and improved treatment (mortality only), among other factors. This study evaluated contemporary national-level trends and their relations with prostate-specific antigen (PSA) testing prevalence and explored trends in incidence according to disease characteristics with stage-specific, delay-adjusted rates.Joinpoint regression was used to examine changes in delay-adjusted prostate cancer incidence rates from population-based US cancer registries from 2000 to 2014 by age categories, race, and disease characteristics, including stage, PSA, Gleason score, and clinical extension. In addition, the analysis included trends for prostate cancer mortality between 1975 and 2015 by race and the estimation of PSA testing prevalence between 1987 and 2005. The annual percent change was calculated for periods defined by significant trend change points.METHODSJoinpoint regression was used to examine changes in delay-adjusted prostate cancer incidence rates from population-based US cancer registries from 2000 to 2014 by age categories, race, and disease characteristics, including stage, PSA, Gleason score, and clinical extension. In addition, the analysis included trends for prostate cancer mortality between 1975 and 2015 by race and the estimation of PSA testing prevalence between 1987 and 2005. The annual percent change was calculated for periods defined by significant trend change points.For all age groups, overall prostate cancer incidence rates declined approximately 6.5% per year from 2007. However, the incidence of distant-stage disease increased from 2010 to 2014. The incidence of disease according to higher PSA levels or Gleason scores at diagnosis did not increase. After years of significant decline (from 1993 to 2013), the overall prostate cancer mortality trend stabilized from 2013 to 2015.RESULTSFor all age groups, overall prostate cancer incidence rates declined approximately 6.5% per year from 2007. However, the incidence of distant-stage disease increased from 2010 to 2014. The incidence of disease according to higher PSA levels or Gleason scores at diagnosis did not increase. After years of significant decline (from 1993 to 2013), the overall prostate cancer mortality trend stabilized from 2013 to 2015.After a decline in PSA test usage, there has been an increased burden of late-stage disease, and the decline in prostate cancer mortality has leveled off. Cancer 2018;124:2801-2814. © 2018 American Cancer Society.CONCLUSIONSAfter a decline in PSA test usage, there has been an increased burden of late-stage disease, and the decline in prostate cancer mortality has leveled off. Cancer 2018;124:2801-2814. © 2018 American Cancer Society. |
| Author | Fedewa, Stacey Jemal, Ahmedin Kohler, Betsy A. Negoita, Serban Henley, S. Jane Petkov, Valentina I. Ma, Jiemin Anderson, Robert N. Feuer, Eric J. Benard, Vicki Cronin, Kathleen A. Dearmon, Barbara J. Penberthy, Lynne Lake, Andrew J. Richardson, Lisa C. Hussey, Sarah K. Mariotto, Angela Sherman, Recinda L. |
| AuthorAffiliation | 5 North American Association of Central Cancer Registries Springfield Illinois 2 Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention Atlanta Georgia 3 National Center for Health Statistics, Centers for Disease Control and Prevention Hyattsville Maryland 1 Division of Cancer Control and Population Sciences National Cancer Institute Bethesda Maryland 6 National Cancer Registrars Association Alexandria Virginia 4 Surveillance and Health Services Research, American Cancer Society Atlanta Georgia 7 Information Management Services, Inc Rockville Maryland |
| AuthorAffiliation_xml | – name: 4 Surveillance and Health Services Research, American Cancer Society Atlanta Georgia – name: 6 National Cancer Registrars Association Alexandria Virginia – name: 7 Information Management Services, Inc Rockville Maryland – name: 5 North American Association of Central Cancer Registries Springfield Illinois – name: 2 Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention Atlanta Georgia – name: 3 National Center for Health Statistics, Centers for Disease Control and Prevention Hyattsville Maryland – name: 1 Division of Cancer Control and Population Sciences National Cancer Institute Bethesda Maryland |
| Author_xml | – sequence: 1 givenname: Serban surname: Negoita fullname: Negoita, Serban email: serban.negoita@nih.gov organization: National Cancer Institute – sequence: 2 givenname: Eric J. surname: Feuer fullname: Feuer, Eric J. organization: National Cancer Institute – sequence: 3 givenname: Angela surname: Mariotto fullname: Mariotto, Angela organization: National Cancer Institute – sequence: 4 givenname: Kathleen A. surname: Cronin fullname: Cronin, Kathleen A. organization: National Cancer Institute – sequence: 5 givenname: Valentina I. surname: Petkov fullname: Petkov, Valentina I. organization: National Cancer Institute – sequence: 6 givenname: Sarah K. orcidid: 0000-0002-6877-6601 surname: Hussey fullname: Hussey, Sarah K. organization: National Cancer Institute – sequence: 7 givenname: Vicki surname: Benard fullname: Benard, Vicki organization: Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention – sequence: 8 givenname: S. Jane surname: Henley fullname: Henley, S. Jane organization: Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention – sequence: 9 givenname: Robert N. surname: Anderson fullname: Anderson, Robert N. organization: National Center for Health Statistics, Centers for Disease Control and Prevention – sequence: 10 givenname: Stacey surname: Fedewa fullname: Fedewa, Stacey organization: Surveillance and Health Services Research, American Cancer Society – sequence: 11 givenname: Recinda L. surname: Sherman fullname: Sherman, Recinda L. organization: North American Association of Central Cancer Registries – sequence: 12 givenname: Betsy A. surname: Kohler fullname: Kohler, Betsy A. organization: North American Association of Central Cancer Registries – sequence: 13 givenname: Barbara J. surname: Dearmon fullname: Dearmon, Barbara J. organization: National Cancer Registrars Association – sequence: 14 givenname: Andrew J. surname: Lake fullname: Lake, Andrew J. organization: Information Management Services, Inc – sequence: 15 givenname: Jiemin surname: Ma fullname: Ma, Jiemin organization: Surveillance and Health Services Research, American Cancer Society – sequence: 16 givenname: Lisa C. surname: Richardson fullname: Richardson, Lisa C. organization: Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention – sequence: 17 givenname: Ahmedin orcidid: 0000-0002-0000-4111 surname: Jemal fullname: Jemal, Ahmedin organization: Surveillance and Health Services Research, American Cancer Society – sequence: 18 givenname: Lynne surname: Penberthy fullname: Penberthy, Lynne organization: National Cancer Institute |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29786851$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kV9rFDEUxYNU7Lb64geQgC8ibk0ySWbGB6EM_lkoFaqCbyGb3OmmzCbTJKP01U9uZrcWLSIEwiW_czg35wgd-OABoaeUnFBC2GvjTTypqODtA7SgpK2XhHJ2gBaEkGYpePXtEB2ldFXGmonqETpkbd3IRtAF-nnq_aQHfAFjiBnngPMG8LnOLnhczjx9zjpPCYced9obiK_wqAu7Wr0pMgM-Y7PR_hISdh6PMaTCAzY7FucI3iasvcXWJdAJZjpqkyG6lJ1Jj9HDXg8Jntzex-jr-3dfuo_Ls08fVt3p2dIIytulNk3dcyLAEru2teRWCtNQK2zft33VS84rqQmVbM0FYcy2QKxsGRAtDBBaHaO3e99xWm_BzsGjHtQY3VbHGxW0U3-_eLdRl-G7koSIWs4GL24NYrieIGW1dcnAMGgPYUqKEc5qwahgBX1-D70KU_RlvUIJyauK1U2hnv2Z6C7K73oK8HIPmPKrKUJ_h1Ci5u7V3L3adV9gcg82Lu-KLNu44d8Supf8cAPc_MdcdefdxV7zCzQQwlQ |
| CitedBy_id | crossref_primary_10_3390_diagnostics11091692 crossref_primary_10_1080_15313204_2024_2443429 crossref_primary_10_1016_j_mehy_2020_109639 crossref_primary_10_3390_pharmaceutics14102051 crossref_primary_10_2147_CMAR_S255817 crossref_primary_10_1097_RLI_0000000000000760 crossref_primary_10_1093_jnci_djab131 crossref_primary_10_1093_jnci_djac066 crossref_primary_10_1002_cnr2_1352 crossref_primary_10_1371_journal_pone_0210434 crossref_primary_10_1039_C9AN01935A crossref_primary_10_1002_cncr_31845 crossref_primary_10_1002_cncr_31846 crossref_primary_10_1007_s00277_022_05041_0 crossref_primary_10_1038_s41598_022_16700_7 crossref_primary_10_1177_15579883211026515 crossref_primary_10_3390_cancers16233995 crossref_primary_10_1016_j_eururo_2020_09_041 crossref_primary_10_18332_tid_204300 crossref_primary_10_1002_cncr_32136 crossref_primary_10_3390_curroncol32080426 crossref_primary_10_1038_s41598_025_07361_3 crossref_primary_10_5534_wjmh_210032 crossref_primary_10_1038_s41598_021_98410_0 crossref_primary_10_1172_JCI166248 crossref_primary_10_1002_onco_13749 crossref_primary_10_1038_s41391_025_01025_z crossref_primary_10_1016_j_ejon_2019_101692 crossref_primary_10_1016_j_urology_2019_10_006 crossref_primary_10_3322_caac_21577 crossref_primary_10_3390_data4030129 crossref_primary_10_1093_carcin_bgab083 crossref_primary_10_1002_cam4_2434 crossref_primary_10_1002_wnan_1555 crossref_primary_10_1259_bjr_20210842 crossref_primary_10_3389_fpubh_2022_811044 crossref_primary_10_1002_cam4_2551 crossref_primary_10_1002_cncr_32801 crossref_primary_10_1002_cncr_32802 crossref_primary_10_1016_j_ijrobp_2022_06_101 crossref_primary_10_3390_bios13030398 crossref_primary_10_1080_03602532_2019_1632886 crossref_primary_10_1186_s42269_023_01106_w crossref_primary_10_1002_cncr_31555 crossref_primary_10_1093_jnci_djz106 crossref_primary_10_1016_j_radonc_2020_07_050 crossref_primary_10_1038_s41416_023_02283_1 crossref_primary_10_1186_s13104_018_3504_5 crossref_primary_10_1155_2021_6691305 crossref_primary_10_1016_j_acuro_2019_08_004 crossref_primary_10_1136_bmjopen_2020_037222 crossref_primary_10_3389_fmed_2021_723396 crossref_primary_10_1007_s00330_023_09438_x crossref_primary_10_4103_aja202259 crossref_primary_10_15585_mmwr_mm6941a1 crossref_primary_10_1093_jnci_djaa068 crossref_primary_10_1038_s41391_020_00298_w crossref_primary_10_1016_j_eururo_2019_08_005 crossref_primary_10_1016_j_urolonc_2021_03_017 crossref_primary_10_1038_s41391_024_00913_0 crossref_primary_10_1001_jamanetworkopen_2022_9025 crossref_primary_10_25100_cm_v50i4_4212 crossref_primary_10_1002_cncr_32630 crossref_primary_10_1002_jmri_27132 crossref_primary_10_1177_1557988318798279 crossref_primary_10_1016_j_clinimag_2022_02_007 crossref_primary_10_1016_j_mehy_2021_110566 crossref_primary_10_1016_j_urology_2020_10_009 crossref_primary_10_3322_caac_21551 crossref_primary_10_1016_j_clgc_2019_01_012 crossref_primary_10_3322_caac_21555 crossref_primary_10_3390_ijerph17228364 crossref_primary_10_1038_s41391_019_0157_y crossref_primary_10_1186_s13045_019_0780_z crossref_primary_10_1111_bcp_13866 crossref_primary_10_1186_s12889_024_20117_4 crossref_primary_10_1002_cnr2_1365 crossref_primary_10_1016_j_compbiomed_2022_105318 crossref_primary_10_1038_s41571_020_0378_y crossref_primary_10_3390_ijms24032185 crossref_primary_10_1001_jamanetworkopen_2021_4708 crossref_primary_10_3322_caac_21708 crossref_primary_10_3390_cancers11081099 crossref_primary_10_1016_j_snb_2023_133417 crossref_primary_10_1186_s13643_020_01450_2 crossref_primary_10_1016_j_clinimag_2022_09_002 crossref_primary_10_3390_epidemiologia4020012 crossref_primary_10_1007_s10585_021_10075_1 crossref_primary_10_3322_caac_21820 crossref_primary_10_1016_j_nut_2023_112164 crossref_primary_10_1080_10641734_2019_1641447 crossref_primary_10_1016_j_clgc_2024_102075 crossref_primary_10_1016_j_critrevonc_2021_103426 crossref_primary_10_1016_j_ctrv_2024_102726 crossref_primary_10_4103_aja202316 crossref_primary_10_1002_pros_70045 crossref_primary_10_1016_j_acuroe_2024_10_002 crossref_primary_10_1016_j_eururo_2020_10_022 crossref_primary_10_1016_j_jmh_2023_100202 crossref_primary_10_3390_antibiotics8030106 crossref_primary_10_1038_s41416_022_02136_3 crossref_primary_10_1093_jnci_djaa092 crossref_primary_10_3390_nu11030633 crossref_primary_10_1080_03007995_2021_1944075 crossref_primary_10_1007_s00330_021_08151_x crossref_primary_10_1038_s41420_023_01682_w crossref_primary_10_1093_oncolo_oyac172 crossref_primary_10_1007_s11606_019_05561_y crossref_primary_10_7759_cureus_32513 crossref_primary_10_3892_mco_2023_2664 crossref_primary_10_3389_fgene_2019_00235 crossref_primary_10_1016_j_eururo_2019_04_001 crossref_primary_10_3322_caac_21654 crossref_primary_10_1177_1073274820902267 crossref_primary_10_3322_caac_21652 crossref_primary_10_1016_j_ymthe_2022_08_019 crossref_primary_10_1093_jncics_pkaa098 crossref_primary_10_1038_s41391_022_00628_0 crossref_primary_10_3389_fimmu_2022_905259 crossref_primary_10_1002_ctm2_495 crossref_primary_10_1016_j_acuroe_2019_08_008 crossref_primary_10_1016_j_urology_2021_01_040 crossref_primary_10_1016_j_nano_2020_102213 crossref_primary_10_1097_PPO_0000000000000422 crossref_primary_10_1177_15330338211004936 crossref_primary_10_1016_j_ctarc_2022_100588 crossref_primary_10_1177_17562872211026421 crossref_primary_10_3892_mmr_2019_10509 crossref_primary_10_1002_pros_24204 crossref_primary_10_1007_s10552_020_01347_4 crossref_primary_10_3322_caac_21763 crossref_primary_10_1155_2022_2118823 crossref_primary_10_1016_j_cryobiol_2021_01_001 crossref_primary_10_1097_PPO_0000000000000688 crossref_primary_10_5435_JAAOS_D_18_00777 crossref_primary_10_1016_j_urolonc_2025_02_011 crossref_primary_10_1038_s41467_022_28069_2 crossref_primary_10_1016_j_acuro_2024_10_001 crossref_primary_10_1016_j_canep_2021_102054 crossref_primary_10_2147_OTT_S258724 crossref_primary_10_1016_j_euo_2021_05_005 crossref_primary_10_1038_s41391_020_0220_8 crossref_primary_10_1002_pros_24212 crossref_primary_10_1001_jamanetworkopen_2022_40657 crossref_primary_10_3892_ol_2019_11134 crossref_primary_10_1007_s00345_020_03363_0 crossref_primary_10_1056_NEJMsr1905447 crossref_primary_10_3892_mco_2018_1724 crossref_primary_10_3322_caac_70028 crossref_primary_10_1016_j_heliyon_2024_e28804 crossref_primary_10_1111_bju_16654 crossref_primary_10_1097_PAP_0000000000000400 crossref_primary_10_3322_caac_21590 crossref_primary_10_1080_10920277_2023_2167834 crossref_primary_10_1200_EDBK_321195 crossref_primary_10_3390_uro3010009 crossref_primary_10_1016_j_urolonc_2020_05_011 crossref_primary_10_1038_s43856_023_00304_x |
| Cites_doi | 10.1016/j.amepre.2017.08.003 10.1056/NEJMoa1702900 10.1097/01.pas.0000173646.99337.b1 10.1097/PAS.0000000000000820 10.1016/j.juro.2017.09.103 10.1093/jnci/94.20.1537 10.1007/s10552-007-9083-8 10.1016/j.urology.2017.04.062 10.1002/cncr.22607 10.1007/978-1-4757-3656-4 10.1002/bimj.201100191 10.1016/S0022-5347(05)63946-8 10.2165/11314830-000000000-00000 10.1093/annonc/mdx742 10.1002/cncr.28932 10.7326/0003-4819-157-2-201207170-00459 10.1001/jama.1995.03520310046028 10.1002/cncr.31551 10.1001/jamaoncol.2016.5465 10.1111/bju.13764 10.7326/0003-4819-149-3-200808050-00008 10.1001/jama.2015.14905 10.1093/jncimonographs/lgs035 |
| ContentType | Journal Article |
| Copyright | 2018 The Authors. published by Wiley Periodicals, Inc. on behalf of . 2018 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. 2018 American Cancer Society |
| Copyright_xml | – notice: 2018 The Authors. published by Wiley Periodicals, Inc. on behalf of . – notice: 2018 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. – notice: 2018 American Cancer Society |
| DBID | 24P AAYXX CITATION CGR CUY CVF ECM EIF NPM 7TO 7U7 C1K H94 K9. NAPCQ 7X8 5PM |
| DOI | 10.1002/cncr.31549 |
| DatabaseName | Wiley Online Library Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Oncogenes and Growth Factors Abstracts Toxicology Abstracts Environmental Sciences and Pollution Management AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium Oncogenes and Growth Factors Abstracts Toxicology Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
| DatabaseTitleList | AIDS and Cancer Research Abstracts MEDLINE CrossRef MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| DocumentTitleAlternate | Recent Changes in Prostate Cancer Trends |
| EISSN | 1097-0142 |
| EndPage | 2814 |
| ExternalDocumentID | PMC6005761 29786851 10_1002_cncr_31549 CNCR31549 |
| Genre | article Research Support, U.S. Gov't, P.H.S Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GeographicLocations | United States |
| GeographicLocations_xml | – name: United States |
| GrantInformation_xml | – fundername: North American Association of Central Cancer Registries – fundername: Merck, Inc – fundername: Centers for Disease Control and Prevention – fundername: American Cancer Society – fundername: National Cancer Institute – fundername: Intramural NIH HHS grantid: Z99 CA999999 |
| GroupedDBID | --- -~X .3N .GA 05W 0R~ 10A 1CY 1L6 1OC 24P 29B 33P 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5VS 66C 6J9 6P2 6PF 702 7PT 8-0 8-1 8-3 8-4 8-5 85S 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANLZ AAONW AARRQ AAWTL AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABHFT ABIJN ABIVO ABJNI ABLJU ABOCM ABPPZ ABPVW ABQWH ABXGK ACAHQ ACCZN ACFBH ACGFO ACGFS ACGOF ACMXC ACNCT ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEIGN AEIMD AENEX AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFRAH AFWVQ AFZJQ AHBTC AIACR AIAGR AITYG AIURR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AZBYB AZVAB BAFTC BAWUL BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM E3Z EBS EJD EMOBN EX3 F00 F01 F04 F5P FD6 FUBAC G-S G.N GNP GODZA GX1 H.X HBH HGLYW HHY HHZ HZ~ IH2 IX1 J0M JPC KBYEO KQQ KZ1 L7B LATKE LAW LC2 LC3 LH4 LITHE LMP LOXES LP6 LP7 LSO LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NNB O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D Q.N Q11 QB0 QRW R.K ROL RWI RX1 RYL SJN SUPJJ TEORI UDS UHB V2E V8K V9Y W8V W99 WBKPD WH7 WHWMO WIH WIJ WIK WIN WJL WOHZO WQJ WRC WVDHM WXI WXSBR XG1 XPP XV2 Z0Y ZGI ZZTAW ~IA ~WT .GJ .Y3 31~ 3O- AAMMB AAQOH AAYXX AEFGJ AEYWJ AFFNX AGHNM AGNAY AGXDD AGYGG AI. AIDQK AIDYY C1A CITATION HF~ H~9 J5H N4W NEJ O8X OHT RSU VH1 WHG Y6R YQJ ZXP CGR CUY CVF ECM EIF NPM 7TO 7U7 C1K H94 K9. NAPCQ 7X8 5PM |
| ID | FETCH-LOGICAL-c5149-ac87f405ed0dbd764d65c81d5dff9f3f64436a0162b45022d9e0d692e0a5ce013 |
| IEDL.DBID | 24P |
| ISICitedReferencesCount | 196 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000435440900020&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0008-543X 1097-0142 |
| IngestDate | Tue Sep 30 16:58:25 EDT 2025 Sun Sep 28 05:35:39 EDT 2025 Sat Nov 29 14:55:37 EST 2025 Mon Jul 21 06:03:14 EDT 2025 Sat Nov 29 07:20:02 EST 2025 Tue Nov 18 21:56:35 EST 2025 Wed Jan 22 16:23:56 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 13 |
| Keywords | Gleason score mortality prostate cancer incidence trends prostate-specific antigen |
| Language | English |
| License | Attribution-NonCommercial 2018 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c5149-ac87f405ed0dbd764d65c81d5dff9f3f64436a0162b45022d9e0d692e0a5ce013 |
| Notes | This article has been contributed to by US Government employees, and their work is in the public domain in the United States. We gratefully acknowledge the contributions of the state and regional cancer registry staff for their work in collecting the data used in this study. In addition, we thank Danny Miller, Joe Zou, Steve Scoppa, and Rick Firth of Information Management Services, Inc, for their assistance in creating the data and generating the results used in this report. The last 2 authors are co‐senior authors. The findings and conclusions in this article are those of the authors and do not necessarily represent the official positions of the author's agencies (the Centers for Disease Control and Prevention, the National Cancer Institute, the American Cancer Society, the North American Association of Central Cancer Registries, and the National Cancer Registrars Association). See companion article and editorial on pages 2785‐800 and 2690‐2, this issue. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0002-6877-6601 0000-0002-0000-4111 |
| OpenAccessLink | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fcncr.31549 |
| PMID | 29786851 |
| PQID | 2056433278 |
| PQPubID | 2045183 |
| PageCount | 14 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_6005761 proquest_miscellaneous_2042752152 proquest_journals_2056433278 pubmed_primary_29786851 crossref_primary_10_1002_cncr_31549 crossref_citationtrail_10_1002_cncr_31549 wiley_primary_10_1002_cncr_31549_CNCR31549 |
| PublicationCentury | 2000 |
| PublicationDate | July 1, 2018 |
| PublicationDateYYYYMMDD | 2018-07-01 |
| PublicationDate_xml | – month: 07 year: 2018 text: July 1, 2018 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Atlanta – name: Hoboken |
| PublicationTitle | Cancer |
| PublicationTitleAlternate | Cancer |
| PublicationYear | 2018 |
| Publisher | Wiley Subscription Services, Inc John Wiley and Sons Inc |
| Publisher_xml | – name: Wiley Subscription Services, Inc – name: John Wiley and Sons Inc |
| References | 2017; 119 2018; 29 2017; 41 2012; 2012 2017; 3 2002; 94 2018; 124 2008; 19 2016; 123 2008; 149 2002 1995; 273 2007; 109 2017; 377 2005; 29 2009; 27 1977 2017; 109 2018; 199 2017; 53 2012; 157 2015; 314 2013; 55 2000 2017 2016 2015 2003; 169 2014; 120 e_1_2_8_28_1 e_1_2_8_29_1 e_1_2_8_25_1 e_1_2_8_26_1 Surveillance, Epidemiology, and End Results Program (e_1_2_8_20_1) 2000 Amin MB (e_1_2_8_24_1) 2016 Surveillance Research Program (e_1_2_8_33_1) 2017 e_1_2_8_3_1 e_1_2_8_2_1 e_1_2_8_5_1 e_1_2_8_4_1 e_1_2_8_7_1 e_1_2_8_6_1 Surveillance, Epidemiology, and End Results Program (e_1_2_8_19_1) 1977 e_1_2_8_9_1 e_1_2_8_8_1 e_1_2_8_43_1 e_1_2_8_21_1 e_1_2_8_42_1 e_1_2_8_22_1 Adamo M (e_1_2_8_27_1) 2016 e_1_2_8_41_1 e_1_2_8_40_1 e_1_2_8_17_1 e_1_2_8_18_1 e_1_2_8_39_1 e_1_2_8_13_1 e_1_2_8_36_1 e_1_2_8_14_1 e_1_2_8_35_1 e_1_2_8_15_1 e_1_2_8_38_1 e_1_2_8_16_1 e_1_2_8_37_1 Thornton ML (e_1_2_8_30_1) 2015 Adamo MP (e_1_2_8_23_1) 2016; 123 e_1_2_8_32_1 e_1_2_8_10_1 e_1_2_8_31_1 e_1_2_8_11_1 e_1_2_8_34_1 e_1_2_8_12_1 30427532 - Cancer. 2019 Jan 15;125(2):317-318. doi: 10.1002/cncr.31846. 30427536 - Cancer. 2019 Jan 15;125(2):318-319. doi: 10.1002/cncr.31845. |
| References_xml | – volume: 109 start-page: 6 year: 2017 end-page: 18 article-title: Predicting response and recognizing resistance: improving outcomes in patients with castration‐resistant prostate cancer publication-title: Urology. – volume: 27 start-page: 533 year: 2009 end-page: 545 article-title: Calibration methods used in cancer simulation models and suggested reporting guidelines publication-title: Pharmacoeconomics. – volume: 149 start-page: 185 year: 2008 end-page: 191 article-title: Screening for prostate cancer: US Preventive Services Task Force recommendation statement publication-title: Ann Intern Med. – volume: 29 start-page: 1228 year: 2005 end-page: 1242 article-title: The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma publication-title: Am J Surg Pathol. – volume: 120 start-page: 3519 year: 2014 end-page: 3526 article-title: Expected population impacts of discontinued prostate‐specific antigen screening publication-title: Cancer. – year: 2000 – start-page: 100 year: 2016 end-page: 101 – volume: 19 start-page: 175 year: 2008 end-page: 181 article-title: Quantifying the role of PSA screening in the US prostate cancer mortality decline publication-title: Cancer Causes Control. – volume: 41 start-page: e1 year: 2017 end-page: e7 article-title: Contemporary Gleason grading of prostatic carcinoma: an update with discussion on practical issues to implement the 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma publication-title: Am J Surg Pathol. – volume: 2012 start-page: 152 year: 2012 end-page: 6 article-title: Trends in prostate cancer in the United States publication-title: J Natl Cancer Inst Monogr. – volume: 94 start-page: 1537 year: 2002 end-page: 1545 article-title: Impact of reporting delay and reporting error on cancer incidence rates and trends publication-title: J Natl Cancer Inst. – year: 2016 – volume: 157 start-page: 120 year: 2012 end-page: 134 article-title: Screening for prostate cancer: US Preventive Services Task Force recommendation statement publication-title: Ann Intern Med. – year: 1977 – volume: 119 start-page: 831 year: 2017 end-page: 845 article-title: First‐line non‐cytotoxic therapy in chemotherapy‐naive patients with metastatic castration‐resistant prostate cancer: a systematic review of 10 randomised clinical trials publication-title: BJU Int. – volume: 109 start-page: 1877 year: 2007 end-page: 1886 article-title: Reconstructing PSA testing patterns between black and white men in the US from Medicare claims and the National Health Interview Survey publication-title: Cancer. – volume: 169 start-page: 517 year: 2003 end-page: 523 article-title: Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer publication-title: J Urol. – volume: 314 start-page: 2054 year: 2015 end-page: 2061 article-title: Prostate cancer incidence and PSA testing patterns in relation to USPSTF screening recommendations publication-title: JAMA. – year: 2002 – volume: 273 start-page: 548 year: 1995 end-page: 552 article-title: The role of increasing detection in the rising incidence of prostate cancer publication-title: JAMA. – volume: 123 start-page: 697 year: 2016 end-page: 703 article-title: Validation of prostate‐specific antigen laboratory values recorded in Surveillance, Epidemiology, and End Results registries publication-title: Cancer. – volume: 53 start-page: 909 year: 2017 end-page: 913 article-title: Patterns of prostate‐specific antigen test use in the U.S., 2005‐2015 publication-title: Am J Prev Med. – volume: 3 start-page: 705 year: 2017 end-page: 707 article-title: Increase in prostate cancer distant metastases at diagnosis in the United States publication-title: JAMA Oncol. – volume: 29 start-page: 377 year: 2018 end-page: 385 article-title: Age at diagnosis and prostate cancer treatment and prognosis: a population‐based cohort study publication-title: Ann Oncol. – year: 2017 – volume: 377 start-page: 338 year: 2017 end-page: 351 article-title: Abiraterone for prostate cancer not previously treated with hormone therapy publication-title: N Engl J Med. – volume: 55 start-page: 755 year: 2013 end-page: 770 article-title: Adjusting for reporting delay in cancer incidence when combining different sets of cancer registries publication-title: Biom J. – volume: 124 start-page: 2785 year: 2018 end-page: 2800 article-title: The annual report to the nation on the status of cancer part I: national cancer statistics publication-title: Cancer – year: 2015 – volume: 199 start-page: 676 year: 2018 end-page: 682 article-title: Trends in prostate cancer incidence rates and prevalence of prostate‐specific antigen screening by socioeconomic status and regions in the US, 2004‐2013 publication-title: J Urol – volume-title: Summary Staging Guide for the Cancer Surveillance, Epidemiology, and End Results (SEER) Program year: 1977 ident: e_1_2_8_19_1 – ident: e_1_2_8_31_1 – ident: e_1_2_8_34_1 doi: 10.1016/j.amepre.2017.08.003 – ident: e_1_2_8_40_1 doi: 10.1056/NEJMoa1702900 – volume-title: AJCC Cancer Staging Manual year: 2016 ident: e_1_2_8_24_1 – ident: e_1_2_8_14_1 – ident: e_1_2_8_17_1 – ident: e_1_2_8_26_1 doi: 10.1097/01.pas.0000173646.99337.b1 – ident: e_1_2_8_22_1 – ident: e_1_2_8_38_1 doi: 10.1097/PAS.0000000000000820 – ident: e_1_2_8_8_1 doi: 10.1016/j.juro.2017.09.103 – ident: e_1_2_8_11_1 doi: 10.1093/jnci/94.20.1537 – volume-title: Summary Staging Guide for the Cancer Surveillance, Epidemiology, and End Results (SEER) Program year: 2000 ident: e_1_2_8_20_1 – volume: 123 start-page: 697 year: 2016 ident: e_1_2_8_23_1 article-title: Validation of prostate‐specific antigen laboratory values recorded in Surveillance, Epidemiology, and End Results registries publication-title: Cancer. – ident: e_1_2_8_42_1 doi: 10.1007/s10552-007-9083-8 – ident: e_1_2_8_43_1 doi: 10.1016/j.urology.2017.04.062 – ident: e_1_2_8_25_1 – ident: e_1_2_8_28_1 – ident: e_1_2_8_32_1 – ident: e_1_2_8_36_1 – ident: e_1_2_8_13_1 doi: 10.1002/cncr.22607 – ident: e_1_2_8_29_1 doi: 10.1007/978-1-4757-3656-4 – ident: e_1_2_8_21_1 – ident: e_1_2_8_12_1 doi: 10.1002/bimj.201100191 – ident: e_1_2_8_37_1 doi: 10.1016/S0022-5347(05)63946-8 – ident: e_1_2_8_35_1 doi: 10.2165/11314830-000000000-00000 – ident: e_1_2_8_10_1 doi: 10.1093/annonc/mdx742 – ident: e_1_2_8_16_1 – ident: e_1_2_8_39_1 doi: 10.1002/cncr.28932 – ident: e_1_2_8_5_1 doi: 10.7326/0003-4819-157-2-201207170-00459 – ident: e_1_2_8_2_1 doi: 10.1001/jama.1995.03520310046028 – ident: e_1_2_8_18_1 doi: 10.1002/cncr.31551 – ident: e_1_2_8_15_1 – ident: e_1_2_8_6_1 doi: 10.1001/jamaoncol.2016.5465 – ident: e_1_2_8_41_1 doi: 10.1111/bju.13764 – ident: e_1_2_8_9_1 – ident: e_1_2_8_4_1 doi: 10.7326/0003-4819-149-3-200808050-00008 – ident: e_1_2_8_7_1 doi: 10.1001/jama.2015.14905 – ident: e_1_2_8_3_1 doi: 10.1093/jncimonographs/lgs035 – start-page: 100 volume-title: SEER Program Coding and Staging Manual 2016 year: 2016 ident: e_1_2_8_27_1 – volume-title: Standards for Cancer Registries Volume II: Data Standards and Data Dictionary, Record Layout Version 16 year: 2015 ident: e_1_2_8_30_1 – volume-title: Joinpoint Regression Program. Version 4.5.0.1 year: 2017 ident: e_1_2_8_33_1 – reference: 30427532 - Cancer. 2019 Jan 15;125(2):317-318. doi: 10.1002/cncr.31846. – reference: 30427536 - Cancer. 2019 Jan 15;125(2):318-319. doi: 10.1002/cncr.31845. |
| SSID | ssj0007253 |
| Score | 2.633348 |
| Snippet | BACKGROUND
Temporal trends in prostate cancer incidence and death rates have been attributed to changing patterns of screening and improved treatment... For the first time, the US cancer surveillance community has performed an analysis of long‐term trends in the incidence of prostate cancer by stage with... Temporal trends in prostate cancer incidence and death rates have been attributed to changing patterns of screening and improved treatment (mortality only),... BACKGROUNDTemporal trends in prostate cancer incidence and death rates have been attributed to changing patterns of screening and improved treatment (mortality... |
| SourceID | pubmedcentral proquest pubmed crossref wiley |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 2801 |
| SubjectTerms | Advisory Committees - standards Age Distribution Aged Cancer Cost of Illness Delay Early Detection of Cancer - standards Early Detection of Cancer - statistics & numerical data Gleason score Humans Incidence Male Mass Screening - standards Mass Screening - statistics & numerical data Middle Aged Mortality Mortality - trends Neoplasm Grading Neoplasm Staging Oncology Original Prevalence Preventive Health Services - standards Prostate cancer Prostate-Specific Antigen - blood prostate‐specific antigen Prostatic Neoplasms - blood Prostatic Neoplasms - diagnosis Prostatic Neoplasms - epidemiology Prostatic Neoplasms - pathology Race Regression analysis SEER Program - statistics & numerical data Trends United States - epidemiology |
| Title | Annual Report to the Nation on the Status of Cancer, part II: Recent changes in prostate cancer trends and disease characteristics |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fcncr.31549 https://www.ncbi.nlm.nih.gov/pubmed/29786851 https://www.proquest.com/docview/2056433278 https://www.proquest.com/docview/2042752152 https://pubmed.ncbi.nlm.nih.gov/PMC6005761 |
| Volume | 124 |
| WOSCitedRecordID | wos000435440900020&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVWIB databaseName: Wiley Online Library Free Content customDbUrl: eissn: 1097-0142 dateEnd: 20241207 omitProxy: false ssIdentifier: ssj0007253 issn: 0008-543X databaseCode: WIN dateStart: 19960101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell – providerCode: PRVWIB databaseName: Wiley Online Library Full Collection 2020 customDbUrl: eissn: 1097-0142 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0007253 issn: 0008-543X databaseCode: DRFUL dateStart: 19960101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpZ1di9QwFIYP667I3vitW12XiN4olm3TfFW8kdHBAR2WxcW5K2mS4oB0humMP8Bf7knS6e6wIohQSkNPaGjPaZ80yXsAXiqrGu64S5ksZMoKkafK6CytcyOcxSqM1yHZhJxO1WxWnu3Bu-1amKgPMfxw85ER3tc-wHXdnV6KhprWrLDHif2bG3CQ54XyiRsoOxvew5L2GpSZSjkrZoM4KT29rLv7ObrGmNenSl5F2PANGt_5v9bfhds9e5L30VnuwZ5r78OtL_3o-gP4FcX2SYRysl4QpEMSlbMJbr7k4XTTkUVDRt5fVm_IEp2PTCZvsZpvPolLiTsyb8nSLylBmCUm2JJ1mIBLdGtJPzDkra8KRj-Ei_HHr6NPaZ-jITWIWmWqjZINQp-zma2tFMwKbpCBuW2asikaxK1CaORKWjOOvGBLl1lRUpdpbhzy5yPYbxetOwJS6gzhpOC5rDnLm0zXRlrsz5XO6502LIFX20dVmV7A3OfR-FFF6WVa-ZtahZuawIvBdhllO_5odbx94lUful1FEQm9qJtUCTwfTmPQ-ZEU3brFxtswKrlPCZzA4-ggw2Uo9ssFcmwCcsd1BgMv6L17pp1_D8Lewi8NFljzdXCdv7S8Gk1H5-Hoyb8YP4VDBD4Vpxsfw_56tXHP4Kb5uZ53q5MQPriXM3UCBx_OxxefsfRtMv0N2PAiqQ |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpZ1ba9RAFMcPWsX64v0SrXpEXyyGZpOZTOKbLJYutkGk4r6FZC64ULLLXvwAfnLPmUnTLhVBhDwkzBkyZM5JfpOZ-R-At4UpnLTSxkJlKhZZPooL3SRxO9K5NVRFyNYnm1BVVUyn5Zd-bQ7vhQn6EMMPN44M_77mAOcf0gcXqqG600sactIA5zrcEEQanLnh-6QaXsQq7UUokyKWIpsO6qTpwUXd7e_RFci8ulbyMsP6j9Dh3f9s_j2409Mnfgzuch-u2e4B3Drp59cfwq8gt48By3E9R-JDDNrZSAdfMZ5uVjh3OGaPWb7HBbkfTiYfqBq3H8Nm4hXOOlzwphLCWdTeFtd-CS42ncF-aoitL0tGP4Jvh59Ox0dxn6Uh1gRbZdzoQjnCPmsS0xqVC5NLTRQsjXOlyxwBV5Y3RJZpKyQRgyltYvIytUkjtSUCfQw73byzTwHLJiE8yeRItVKMXNK0Whka0ZWWFU-diODdeV_Vupcw50waZ3UQX05rfqi1f6gRvBlsF0G4449We-ddXvfBu6pTgkKWdVNFBK-HYgo7nktpOjvfsI1IleSkwBE8CR4y3CalkXlOJBuB2vKdwYAlvbdLutkPL-2d8-bgnGrue9_5S8vrcTX-6s-e_YvxK9g9Oj05ro8n1efncJvwrwiLj_dgZ73c2BdwU_9cz1bLlz6WfgMJzyNq |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpZ1ba9RAFMcPupXii_dLtOqIvigNzSZzSXyTrYuLdSnFwr6FZC64INllL34AP7nnzEzTLhVBhDwk5AxJZs5JfpOZ-R-At6UpnbDCplwVKuWFHKalbrK0HWppDRbhovXJJtR0Ws5m1Wmcm0NrYYI-RP_DjSLDv68pwO3SuKNL1VDd6RV2ObGDcxP2OGWRGcDe8dn4_KR_Fas8ylBmZSp4Mev1SfOjy9K7X6RrmHl9tuRVivWfofHd_3yAe3An8if7GBzmPtyw3QPY_xpH2B_CryC4zwKYs82CISGyoJ7NcKMjAtTtmi0cG5HPrA7ZEh2QTSYfsBjdPwvLidds3rElLStBoGXa27KNn4TLms6wODhE1ldFox_B-fjTt9HnNOZpSDXiVpU2ulQOwc-azLRGSW6k0MjBwjhXucIhchWyQbbMWy6QGUxlMyOr3GaN0BYZ9DEMukVnnwKrmgwBpRBD1Qo-dFnTamWwT1dZ0jx1PIF3F21V6yhiTrk0ftRBfjmvqVJrX6kJvOltl0G6449WBxdNXsfwXdc5YiEJu6kygdf9aQw8Gk1pOrvYkg3PlaC0wAk8CR7SXybHvrlElk1A7fhOb0Ci3rtnuvl3L-4taXmwxJLvve_85c7r0XR05vee_YvxK9g_PR7XJ5Ppl-dwG_mvDLOPD2CwWW3tC7ilf27m69XLGEy_AfgDJBM |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Annual+Report+to+the+Nation+on+the+Status+of+Cancer%2C+part+II%3A+Recent+changes+in+prostate+cancer+trends+and+disease+characteristics&rft.jtitle=Cancer&rft.au=Negoita%2C+Serban&rft.au=Feuer%2C+Eric+J&rft.au=Mariotto%2C+Angela&rft.au=Cronin%2C+Kathleen+A&rft.date=2018-07-01&rft.issn=1097-0142&rft.eissn=1097-0142&rft.volume=124&rft.issue=13&rft.spage=2801&rft_id=info:doi/10.1002%2Fcncr.31549&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0008-543X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0008-543X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0008-543X&client=summon |